Skip to main content
. 2024 Oct 21;46(6):16. doi: 10.1007/s00281-024-01025-6

Fig. 3.

Fig. 3

Glycan-associated immunotherapeutic approaches in ovarian cancer. Several preclinical and clinical trials studying the efficacy of glycan-specific antibodies, glycan-specific antibody drug conjugates, glycan-directed CAR T cells or glycan-based vaccines are ongoing or have been conducted. The main glycan structures targeted are STn, Tn, Globo-H, Lewis Y, and sialoglycans. This figure was created via BioRender.com